| http://purl.uniprot.org/citations/12705339 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/12705339 | http://www.w3.org/2000/01/rdf-schema#comment | "The aim of this study was to evaluate the diagnostic and prognostic values of serum angiogenin concentration in cases with gestational trophoblastic diseases (GTDs). Seventy-two patients with GTDs and 20 first trimester healthy pregnant women (controls) participated in this study. According to the WHO scoring system, GTDs were subgrouped into 24 hydatiform mole spontaneous regression (HMSR), 18 postmolar gestational trophoblastic tumors of high risk (PMHR), 16 low-risk choriocarcinoma, and 14 high-risk choriocarcinoma. Before treatment, a blood sample from each case was assayed for human chorionic gonadotrophin , subunit (hCGb) by radioimmunoassay and angiogenin by enzyme immunoassay. Follow-up hCGb and angiogenin assays were carried out for 1 year after treatment. Pretreatment of abnormal values of serum angiogenin (> 711 ng/ml, upper 95% confidence interval of controls) was encountered in 100% of PMHR cases compared to no single case of HMSR. Serum angiogenin levels in low- and high-risk cases with choriocarcinoma were significantly higher than in controls. Abnormal high values were encountered in 25% and 86% of cases, respectively. None of the low-risk cases exceeded 920 ng/ml, while 72% of high-risk cases exceeded this value. Serial angiogenin assays were correlated with disease progression and were positively correlated with serum hCGb (r = 0.75, p < 0.01). In conclusion, serum angiogenin may be a valuable marker of differential diagnosis of GTDs and its serial measurements are suggestive of remission and effective therapeutic intervention or disease progression."xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.org/dc/terms/identifier | "doi:10.1515/cclm.2003.049"xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/author | "El-Mallah S.Y."xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/author | "Shaarawy M."xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/author | "Sheiba M."xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/date | "2003"xsd:gYear |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/name | "Clin Chem Lab Med"xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/pages | "306-310"xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/title | "Angiogenin and gestational trophoblastic tumors, a promising prognostic marker."xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://purl.uniprot.org/core/volume | "41"xsd:string |
| http://purl.uniprot.org/citations/12705339 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/12705339 |
| http://purl.uniprot.org/citations/12705339 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/12705339 |
| http://purl.uniprot.org/uniprot/#_P03950-mappedCitation-12705339 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/12705339 |
| http://purl.uniprot.org/uniprot/#_W0UV28-mappedCitation-12705339 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/12705339 |
| http://purl.uniprot.org/uniprot/P03950 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/12705339 |
| http://purl.uniprot.org/uniprot/W0UV28 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/12705339 |